U nas zapłacisz kartą
Vita C Infusion Mikrodermabrazja - Twoje Klucze do Promiennej Skóry
Concluding Remarks
Vitamin C as a cancer therapy has had a controversial past. What has been intriguing are small clinical trials that suggest some responses, but with no clear rationale for why cancers should respond to vitamin C or a path forward for explaining which patients are most likely to respond. Now a growing number of preclinical studies are showing how high-dose vitamin C might benefit cancer patients. Importantly, these preclinical studies provide a clear rationale and potential biomarkers that may help personalize the therapeutic approach and identify patient populations that are likely to respond to high-dose vitamin C therapy. Since the mechanisms of action of vitamin C are becoming better defined, we can propose vitamin C combinations in a more rational, hypothesis-driven manner. In addition, given the current high financial cost of new cancer drugs, it seems rational to improve the effectiveness of current therapies by studying their clinical interactions with vitamin C. In our view, the implementation of this treatment paradigm could provide benefit to many cancer patients.
This work was supported by the US National Institutes of Health (NIH) grant (R35 CA197588), Stand Up to Cancer–American Association for Cancer Research grant (SU2C-AACR-DT22-17), and the Damon Runyon Cancer Research Foundation. Lewis Cantley is a founder and member of the senior advisory boards of Agios Pharmaceuticals and Petra Pharmaceuticals, which are developing novel therapies for cancer. The Cantley laboratory also receives financial support from Petra Pharmaceuticals.
Taking RAS Research to Space
The controversial history of high-dose vitamin C in cancer treatment
Utilizing high doses of vitamin C as a cancer therapy is no exception to this controversy. Nearly 60 years ago Toronto physician William McCormick observed that cancer patients often presented with severely low levels of vitamin C in their blood and featured scurvy-like symptoms, leading him to postulate that vitamin C might protect against cancer by increasing collagen synthesis. In 1972, extending this theory, Ewan Cameron, a Scottish surgeon, hypothesized that ascorbate could suppress cancer development by inhibiting hyaluronidase, which otherwise weakens the extracellular matrix and enables cancer to metastasize. He began treating terminally ill cancer patients and published a case report of 50 patients in which some of the treated patients benefited from high dose vitamin C.
So why did the Pauling and Mayo Clinic trials have different results? There are at least two crucial differences. First, the Mayo Clinic trials abruptly stopped the ascorbate administration, switching to traditional chemotherapy, when the patient developed signs of tumor progression. Thus, the overall median time of vitamin C treatment under the Mayo Clinic trials was only 2.5 months, while the Pauling and Cameron trials treated patients for the duration of the entire study period or as long as 12 years. Secondly, the Mayo Clinic trials administered 10 g of daily ascorbate to patients only orally, while the Cameron and Pauling trials administered their vitamin C both orally and intravenously. This difference in the two dosage routes proved highly consequential.
Recenzje 69
- Od najwyższej oceny
- Od najniższej oceny
- Sortowanie domyślne
- Od najstarszych
Dodanych produktów: 4
Napisanych recenzji: 826
4 / 5
25 marca 2023, o 19:48
Nie wie, czy kupi ponownie
Używa produktu od: miesiąc
Wykorzystała: jedno opakowanie
Kupiony w: Drogeria Rossmann
Pięknie pachnie.
Kosmetyk pachnie cytrusowo, dosyć intensywnie. Kosmetyk jest żółtawy. Na skórze czuć drobinki, które masują moją skórę. Zauważyłam lekkie rozjaśnienie mojej skóry. Peeling stosuję regularnie eaz q tygodniu. Nie czuję podrażnienia ani uczulenia. Nie należy mocno masować skóry twarzy ponieważ może zaistnieć zaczerwienienie.
Dodanych produktów: 25
Napisanych recenzji: 62
5 / 5
6 lutego 2021, o 11:11
Nie wie, czy kupi ponownie
Używa produktu od: kilka miesięcy
Wykorzystała: jedno opakowanie
Kupiony w: Nie podano
Bardzo fajny
Kupiłam ten peeling z przypadku i pozytywnie mnie zaskoczył.
Opakowanie proste, wygodne w użyciu.
Zapach delikatny, przyjemny.
Nie spowodował u mnie uczulenia ani wysuszenia.
Skóra po użyciu jest zdecydowanie wygładzona, czuć że została wypeelingowana. Nie jest pozdzierana. Konsystencja lekkiego kremu z malutkimi drobinkami ledwo wyczuwalnymi pod palcami, nie spodziewałam się że tak fajnie zadziała.
ZALETY: opakowanie
działanie
zapach
Dodanych produktów: 0
Napisanych recenzji: 1173
5 / 5
14 listopada 2020, o 21:55
Używa produktu od: rok lub dłużej
Wykorzystała: jedno opakowanie
Intravenous High-Dose Vitamin C in Cancer Therapy
Lewis Cantley received his Ph.D. from Cornell University and did his post-doctoral work at Harvard University. He was formerly a professor in the Departments of Systems Biology and Medicine at Harvard Medical School in Boston. He is current the Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. Jihye Yun received her Ph.D. from Johns Hopkins University, School of Medicine under the mentorship of Bert Vogelstein and did her post-doctoral work with Lewis Cantley at Weill Cornell Medicine. She is currently an Assistant Professor and a CPRIT scholar at Baylor College of Medicine in Houston.
The discovery and isolation of vitamin C was one of the most important advances in improving human nutrition. Scurvy, a severe vitamin C deficiency disease characterized by weakness, lethargy, easy bruising and bleeding, was particularly problematic for sailors on long voyages during the 16th century, where access to fresh fruits and vegetables was limited. In fact, scurvy was the leading cause of naval deaths between the 16th and 18th centuries, killing more sailors than all battles, storms and other diseases combined. It wasn’t until 1747 that Scottish naval physician James Lind demonstrated that consuming oranges and lemons cured and prevented scurvy. However, it took scientists nearly two more centuries to identify the nature of the curative substance contained in citrus fruits, now commonly known as vitamin C. The search for this elusive substance ended in 1932 when Albert Szent-Gyorgyi, a Hungarian biochemist, isolated and identified a 6-carbon carbohydrate, hexuronic acid, as the anti-scurvy factor. Shortly thereafter, Szent-Gyorgyi renamed it “a-scorbic acid”, a reference to its anti-scorbutic properties, and later went on to receive the Nobel Prize in Physiology and Medicine in 1937 for his discoveries.
